Edition:
Deutschland

Daiichi Sankyo Co Ltd (4568.T)

4568.T on Tokyo Stock Exchange

4,323JPY
15 Aug 2018
Change (% chg)

-- (--)
Prev Close
¥4,323
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,958,826
52-wk High
¥4,820
52-wk Low
¥2,284

4568.T

Chart for 4568.T

About

DAIICHI SANKYO COMPANY, LIMITED is a Japan-based holding company mainly engaged in the manufacture and sale of pharmaceuticals. The Company is involved in the research, development, manufacture and sale of pharmaceuticals, as well as the provision of intermediates and basic materials for pharmaceutical producing in Japan, the... (more)

Buy/Sell

Sell Hold Buy
2.58 Mean rating from 12 analysts

Overall

Beta: 0.84
Market Cap(Mil.): ¥1,772,528.00
Shares Outstanding(Mil.): 709.01
Dividend: 35.00
Yield (%): 2.80

Nikkei flat in choppy trade as trade war woes pressures; Kikkoman soars

TOKYO, June 20 Japan's Nikkei share average was flat in choppy trade on Wednesday morning as firms that rely on China demand tumbled on trade war worries, with machine tool makers and shippers posting multi-month lows, which offset gains in defensive stocks.

Nikkei drops after Trump quits Iran nuclear deal; Toyota shines after earnings

TOKYO, May 9 Japanese stocks fell on Wednesday as global tensions flared after President Donald Trump pulled the United States out of an international nuclear deal with Iran, but Toyota rose after releasing earnings and announcing a share buyback.

Nikkei drops after Trump quits Iran nuclear deal; Toyota's results eyed

TOKYO, May 9 Japanese stocks slipped on Wednesday morning as investors were cautious after U.S. President Donald Trump pulled the United States out of an international nuclear deal with Iran.

BRIEF-Thermo Fisher Scientific Signs New Agreements To Expand Oncomine Dx Target Test

* THERMO FISHER SCIENTIFIC SIGNS NEW AGREEMENTS TO EXPAND ONCOMINE DX TARGET TEST

BRIEF-Daiichi Sankyo to reorganize Kitasato Daiichi Sankyo Vaccine into specialized manufacturing unit

* Says it plans to reorganize unit Kitasato Daiichi Sankyo Vaccine Co., Ltd. into a unit specializing in manufacturing, effective April 1, 2019

BRIEF-Vaxart Announces $5 Mln Inavir Revenue Milestone

* VAXART - NOTIFIED BY DAIICHI SANKYO CO THAT SALES OF INAVIR EXCEEDED ¥20 BILLION IN FISCAL YEAR 2017, TRIGGERING A $5 MILLION MILESTONE PAYMENT TO CO

CORRECTED-UPDATE 3-China's Fosun becomes fourth suitor for India's troubled Fortis

* Fortis says Fosun offered up to $350 mln for under 25 pct stake

BRIEF-‍Daiichi Sankyo And Darwinhealth Enter Exclusive Research Collaboration For Novel Cancer Target Initiative​

* ‍DAIICHI SANKYO AND DARWINHEALTH ENTER EXCLUSIVE RESEARCH COLLABORATION FOR NOVEL CANCER TARGET INITIATIVE​

Photo

Manipal in deal to buy Fortis hospitals, set to face Fortis shareholder ire

BANGALORE/MUMBAI India's Manipal Hospitals Enterprises Private Ltd plans to buy troubled Fortis Healthcare Ltd's hospital business, but the deal is expected to run into opposition from Fortis minority shareholders whose shares plunged 14 percent on the news.

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie -2.06%
Rohstoffe -0.68%
Industrie -1.05%
Konjunktur abhängige Waren & Dienstleistungen -0.09%
Konjunktur unabhängige Waren & Dienstleistungen -0.51%
Finanzindustrie -0.32%
Pharma -1.11%
Technologie -0.05%
Telekommunikation +0.37%